Combination of Gemfibrozil and Orlistat for Treatment of Combined Hyperlipidemia With Predominant Hypertriglyceridemia
Authors:
- Andrea FerencziAFAndrea Ferenczi
- Laura RonenLRLaura Ronen
- Leonid PoretskyLPLeonid Poretsky
- 1 May 2002
- journal article
- case report
- Published by Elsevier in Endocrine Practice
- Vol. 8 (3) , 208-212
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery DiseaseCirculation, 2000
- Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteersInternational Journal of Obesity, 2000
- Orlistat in the Long-term Treatment of Obesity in Primary Care SettingsArchives of Family Medicine, 2000
- Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for ObesityObesity Research, 2000
- Orlistat: Selective Inhibition of Caloric Absorption Can Affect Long-Term Body WeightEndocrine, 2000
- Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemiasBritish Journal of Clinical Pharmacology, 1999
- Establishment of a clinically correlated human pericardial fluid bank: Evaluation of intrapericardial diagnostic potentialClinical Cardiology, 1999
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987